Literature DB >> 22129598

Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers.

Leen H Kawas1, Alene T McCoy, Brent J Yamamoto, John W Wright, Joseph W Harding.   

Abstract

The 6-AH family [D-Nle-X-Ile-NH-(CH(2))(5)-CONH(2); where X = various amino acids] of angiotensin IV (Ang IV) analogs binds directly to hepatocyte growth factor (HGF) and inhibit HGF's ability to form functional dimers. The metabolically stabilized 6-AH family member, D-Nle-Tyr-Ile-NH-(CH(2))(5)-CONH(2,) had a t(1/2) in blood of 80 min compared with the parent compound norleual [Nle-Tyr-Leu-Ψ-(CH(2)-NH(2))(3-4)-His-Pro-Phe], which had a t(1/2) in blood of <5 min. 6-AH family members were found to act as mimics of the dimerization domain of HGF (hinge region) and inhibited the interaction of an HGF molecule with a (3)H-hinge region peptide resulting in an attenuated capacity of HGF to activate its receptor Met. This interference translated into inhibition of HGF-dependent signaling, proliferation, and scattering in multiple cell types at concentrations down into the low picomolar range. We also noted a significant correlation between the ability of the 6-AH family members to block HGF dimerization and inhibition of the cellular activity. Furthermore, a member of the 6-AH family with cysteine at position 2, was a particularly effective antagonist of HGF-dependent cellular activities. This compound suppressed pulmonary colonization by B16-F10 murine melanoma cells, which are characterized by an overactive HGF/Met system. Together, these data indicate that the 6-AH family of Ang IV analogs exerts its biological activity by modifying the activity of the HGF/Met system and offers the potential as therapeutic agents in disorders that are dependent on or possess an overactivation of the HGF/Met system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129598     DOI: 10.1124/jpet.111.188136

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

2.  Angiotensin IV is induced in experimental autoimmune encephalomyelitis but fails to influence the disease.

Authors:  Arndt Manzel; Oliver Domenig; Bjoern Ambrosius; Agnes Kovacs; Johannes Stegbauer; Marko Poglitsch; Dominik N Mueller; Ralf Gold; Ralf A Linker
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-23       Impact factor: 4.147

3.  Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.

Authors:  Alene T McCoy; Caroline C Benoist; John W Wright; Leen H Kawas; Jyote M Bule-Ghogare; Mingyan Zhu; Suzanne M Appleyard; Gary A Wayman; Joseph W Harding
Journal:  J Pharmacol Exp Ther       Date:  2012-10-10       Impact factor: 4.030

4.  The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system.

Authors:  Caroline C Benoist; Leen H Kawas; Mingyan Zhu; Katherine A Tyson; Lori Stillmaker; Suzanne M Appleyard; John W Wright; Gary A Wayman; Joseph W Harding
Journal:  J Pharmacol Exp Ther       Date:  2014-09-03       Impact factor: 4.030

5.  Importance of the brain Angiotensin system in Parkinson's disease.

Authors:  John W Wright; Joseph W Harding
Journal:  Parkinsons Dis       Date:  2012-11-07

6.  Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure.

Authors:  Phillip M Uribe; Leen H Kawas; Joseph W Harding; Allison B Coffin
Journal:  Front Cell Neurosci       Date:  2015-01-28       Impact factor: 5.505

7.  Inhibition of Insulin-Regulated Aminopeptidase (IRAP) by Arylsulfonamides.

Authors:  Sanjay R Borhade; Ulrika Rosenström; Jonas Sävmarker; Thomas Lundbäck; Annika Jenmalm-Jensen; Kristmundur Sigmundsson; Hanna Axelsson; Fredrik Svensson; Vivek Konda; Christian Sköld; Mats Larhed; Mathias Hallberg
Journal:  ChemistryOpen       Date:  2014-11-21       Impact factor: 2.911

Review 8.  A Role for the Brain RAS in Alzheimer's and Parkinson's Diseases.

Authors:  John W Wright; Leen H Kawas; Joseph W Harding
Journal:  Front Endocrinol (Lausanne)       Date:  2013-10-25       Impact factor: 5.555

9.  The Hepatocyte Growth Factor/c-Met Antagonist, Divalinal-Angiotensin IV, Blocks the Acquisition of Methamphetamine Dependent Conditioned Place Preference in Rats.

Authors:  John W Wright; Wendy L Wilson; Vanessa Wakeling; Alan S Boydstun; Audrey Jensen; Leen Kawas; Joseph W Harding
Journal:  Brain Sci       Date:  2012-08-20

10.  Angiotensin IV suppresses inflammation in the brains of rats with chronic cerebral hypoperfusion.

Authors:  Qing-Guang Wang; Xiao Xue; Yang Yang; Peng-Yu Gong; Teng Jiang; Ying-Dong Zhang
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Jul-Sep       Impact factor: 1.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.